dapirolizumab pegol

Home
Ligands
dapirolizumab pegol

GtoPdb Ligand ID: 11123

Synonyms: CDP-7657 | CDP7657 | DZP

Comment: Dapirolizumab pegol (CDP7657) is a pegylated monovalent Fab' immunomodulator that targets CD40 ligand [1]. It was developed by UCB Pharma. Removal of the Fc domain prevented the increased risk of thrombotic events observed with an intact mAb.

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Dapirolizumab pegol blocks the stimulatory CD40/CD40 ligand immune checkpoint. It is being investigated for potential to subdue abnormal activation of the immune system in autoimmune disease.

Immunopharmacology Comments

Dapirolizumab pegol blocks the stimulatory CD40/CD40 ligand immune checkpoint. It is being investigated for potential to subdue abnormal activation of the immune system in autoimmune disease.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Systemic lupus erythematosus	Disease Ontology: DOID:9074 OMIM: 152700 Orphanet: ORPHA536	Clinical candidate for the treatment of SLE.